Wednesday, May 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home CBRNE

Chemical Threat Countermeasures Cooperative Research Projects

by Global Biodefense Staff
April 26, 2013

Laboratory ResearchThe National Institutes of Health has issued a funding opportunity announcement seeking grant applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Research Projects (U01s).

The mission of the CounterACT U01 program is to develop new and improved therapeutics for chemical threats to reduce mortality and morbidity during and after emergency events involving the release of chemical threat agents.

Chemical threat agents are toxic chemicals that could cause mass casualties after being released by a deliberate terrorist attack, or by industrial accident or natural disaster. The purpose of the U01 funding opportunity is to foster and support the development of Food and Drug Administration (FDA)-approved therapeutics that can be used effectively to treat individuals during a chemical emergency event.

The current effort only supports translational research which is clearly relevant to the development of therapeutics that will enhance medical response capabilities during a chemical emergency. The categories of research supported under this program may include:           

  • Mechanistic research to identify targets for therapeutic development
  • Creation and development of screening assays for therapy development
  • Creation and validation of animal models of chemical effects on humans
  • Identification of candidate therapeutics using primary/secondary screening efforts
  • Development of proof-of-principle data on the efficacy of candidate therapeutics
  • Advanced efficacy studies with appropriate animal models
  • Preliminary and advanced preclinical research including safety and pharmacokinetic studies

Letters of intent are due August 16, 2013. Further details are available under FOA Number: PAR-13-208.

Tags: Animal Models

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC